Clinical Trial Update: Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sub-tenon Triamcinolone acetonide as an adjunct to Ranibizumab for wet age-related macular degeneration. Current status of the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)
• TRIAMCINOLONE ACETONIDE (TRIAMCINOLONE ACETONIDE)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Wet Macular Degeneration | Phase 2 | Status: UNKNOWN